



May 16, 2011

Biomarker Recommendations Published from iSBTc-SITC/FDA/NCI Workshop

Cancer immunotherapy has recently seen a number of clinical successes, yet immunological biomarkers to identify patients most likely to benefit from cancer immunotherapy and guide treatment remain elusive. To promote biomarker development and validation, Lisa Butterfield, PhD (University of Pittsburgh) and members of the SITC Taskforce on Immunotherapy Biomarkers have recently published [Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers](#), which appeared in the May 15 issue of the journal *Clinical Cancer Research*. The summary document resulted from meetings organized by SITC with FDA and NCI participation, and in collaboration with 10 organizations with representation of 20 countries. The recommendations emphasize standardization of immunological assays, banking of blood and tissue, development and application of high throughput assays, and standardization of data reporting to improve assessment of responders and non-responders as well as evaluation of mechanisms of action and novel hypotheses related to cancer immunotherapies.

We congratulate the authors and members of the collaborative taskforce and the [participating organizations](#) for their efforts to develop these recommendations to advance biomarkers research and clinical immunotherapy strategies to improve cancer outcomes.

Thomas F. Gajewski, MD, PhD
President, Society for Immunotherapy of Cancer (SITC, formerly iSBTc)
Professor, Department of Pathology and Department of Medicine
Section of Hematology/Oncology
University of Chicago